Recently, Cerignoli et al. developed the real-time, impedance-monitoring system to assess immune-checkpoint inhibitors using prostate cancer PC3 cells, in combination with an anti- programmed cell death-1 (PD-1) antibody and peripheral blood mononuclear cells (PBMCs) [27]. This evidence concerns the gene PDCD1 and prostate cancer.